StocksHigh ImpactUpdated×2•Originally published 6 May 2026•Updated 6 May 2026•
1 min read
TG Therapeutics Stock Surges as H.C. Wainwright Raises Price Target to $70
Key Facts
1H.C. Wainwright raised its price target for TGTX to $70, suggesting a potential 76.1% upside.
2The company reported Q1 2026 revenues of approximately $205 million, driven by BRIUMVI sales.
3TG Therapeutics raised its full-year global revenue target to approximately $925 million.
H.C. Wainwright has significantly raised its price target for TG Therapeutics (TGTX) to $70, implying a potential upside of 76.1%. The revision follows a robust Q1 2026 performance where the company reported revenues of approximately $205 million. This growth was primarily fueled by the success of its flagship product, BRIUMVI, which generated $195 million in U.S. net revenue. Consequently, TG Therapeutics has upgraded its full-year global revenue guidance to approximately $925 million. The market responded bullishly to the news, with the stock price surging 10.51% to hit a new 52-week high. Analysts view this upward revision as a testament to the company's strengthening commercial position in the biotechnology sector.